Healthcare provider profile · identity verified

Hope R Smith

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · HOPKINSVILLE, KY · NPI 1922482587

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Hope R Smith received $65,154.04 in general payments during 2025 across 232 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 76.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 20 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Caplyta, Fanapt, Ingrezza, Invega Sustenna, Lybalvi, Rexulti, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lybalvi by this doctor in 2024.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Invega Sustenna by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xarelto by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abilify Maintena by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$65,154.04

232 reported records · 14 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$49,738.19	76.3%	123	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$14,094.29	21.6%	22	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$309.10	0.5%	18	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$236.19	0.4%	19	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$230.87	0.3%	14	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$151.33	0.2%	13	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$84.95	0.1%	5	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$83.97	0.1%	5	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$61.71	0.1%	4	2025
Corium, LLC	Unresolved — no canonical attribution shown	$55.62	0.1%	3	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$39.85	0.1%	2	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$29.97	0.1%	2	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$21.33	0.0%	1	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$16.67	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$52,096.00	36
Travel and Lodging	$6,991.14	40
Food and Beverage	$3,455.41	153
Consulting Fee	$2,500.00	2
Education	$111.49	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$49,738.19	123	2025
Source payment records 2025-01-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.55 · Open Payments source 2025-01-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.46 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.96 · Open Payments source 2025-03-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.48 · Open Payments source 2025-03-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.59 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.50 · Open Payments source 2025-04-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-04-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.62 · Open Payments source 2025-05-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.12 · Open Payments source 2025-05-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.27 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.48 · Open Payments source 2025-06-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.89 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.97 · Open Payments source 2025-06-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.97 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.60 · Open Payments source 2025-07-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.04 · Open Payments source 2025-07-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.37 · Open Payments source 2025-07-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.16 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.44 · Open Payments source 2025-07-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.54 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $229.60 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $800.00 · Open Payments source 2025-07-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.69 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.93 · Open Payments source 2025-08-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-08-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.08 · Open Payments source 2025-08-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $135.41 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $800.00 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $70.00 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.20 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $95.90 · Open Payments source 2025-08-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $900.00 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.37 · Open Payments source 2025-08-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.72 · Open Payments source 2025-08-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,800.00 · Open Payments source 2025-08-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.93 · Open Payments source 2025-08-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.62 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.80 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $140.70 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $165.20 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $48.30 · Open Payments source 2025-08-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.37 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.85 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.56 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.67 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $231.00 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $200.90 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.41 · Open Payments source 2025-09-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.40 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $800.00 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $132.32 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $364.00 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $128.80 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $96.60 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-10-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.49 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $358.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.91 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $185.32 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.66 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $264.60 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.50 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.72 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $207.20 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,800.00 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $257.09 · Open Payments source 2025-10-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.90 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.61 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.03 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-11-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $309.40 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.45 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $62.80 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.10 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.96 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $800.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,600.00 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.54 · Open Payments source 2025-11-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.83 · Open Payments source 2025-11-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.45 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $133.70 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.60 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $103.60 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.20 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $181.30 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,000.00 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-11-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,600.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.95 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.57 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $117.60 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.90 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,600.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,600.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,800.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $600.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,400.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $261.80 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $66.50 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $170.80 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $226.80 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $170.80 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $215.60 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $800.00 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$13,949.43	19	2025
Source payment records 2025-04-23 · Teva Pharmaceuticals USA, Inc. · $2,963.00 · Open Payments source 2025-04-29 · Teva Pharmaceuticals USA, Inc. · $106.40 · Open Payments source 2025-04-29 · Teva Pharmaceuticals USA, Inc. · $124.66 · Open Payments source 2025-04-29 · Teva Pharmaceuticals USA, Inc. · $2,183.00 · Open Payments source 2025-05-13 · Teva Pharmaceuticals USA, Inc. · $120.33 · Open Payments source 2025-05-13 · Teva Pharmaceuticals USA, Inc. · $182.42 · Open Payments source 2025-05-13 · Teva Pharmaceuticals USA, Inc. · $2,519.00 · Open Payments source 2025-05-15 · Teva Pharmaceuticals USA, Inc. · $6.28 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $28.00 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $108.81 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $233.33 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $378.00 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $2,855.00 · Open Payments source 2025-06-24 · Teva Pharmaceuticals USA, Inc. · $1.10 · Open Payments source 2025-06-24 · Teva Pharmaceuticals USA, Inc. · $26.21 · Open Payments source 2025-07-29 · Teva Pharmaceuticals USA, Inc. · $123.29 · Open Payments source 2025-07-29 · Teva Pharmaceuticals USA, Inc. · $1,680.00 · Open Payments source 2025-08-14 · Teva Pharmaceuticals USA, Inc. · $14.60 · Open Payments source 2025-11-30 · Teva Pharmaceuticals USA, Inc. · $296.00 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$294.17	17	2025
Source payment records 2025-01-15 · Alkermes, Inc. · $20.40 · Open Payments source 2025-01-23 · Alkermes, Inc. · $19.54 · Open Payments source 2025-02-13 · Alkermes, Inc. · $3.67 · Open Payments source 2025-03-06 · Alkermes, Inc. · $25.18 · Open Payments source 2025-03-13 · Alkermes, Inc. · $2.71 · Open Payments source 2025-03-13 · Alkermes, Inc. · $6.76 · Open Payments source 2025-05-19 · Alkermes, Inc. · $97.62 · Open Payments source 2025-05-22 · Alkermes, Inc. · $18.58 · Open Payments source 2025-07-10 · Alkermes, Inc. · $5.08 · Open Payments source 2025-07-24 · Alkermes, Inc. · $17.44 · Open Payments source 2025-08-05 · Alkermes, Inc. · $12.21 · Open Payments source 2025-09-23 · Alkermes, Inc. · $1.93 · Open Payments source 2025-09-23 · Alkermes, Inc. · $9.37 · Open Payments source 2025-10-08 · Alkermes, Inc. · $21.41 · Open Payments source 2025-11-18 · Alkermes, Inc. · $1.11 · Open Payments source 2025-11-18 · Alkermes, Inc. · $14.32 · Open Payments source 2025-12-09 · Alkermes, Inc. · $16.84 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$236.19	19	2025
Source payment records 2025-02-06 · E.R. Squibb & Sons, L.L.C. · $3.01 · Open Payments source 2025-02-06 · E.R. Squibb & Sons, L.L.C. · $24.19 · Open Payments source 2025-02-11 · E.R. Squibb & Sons, L.L.C. · $9.88 · Open Payments source 2025-02-18 · E.R. Squibb & Sons, L.L.C. · $11.36 · Open Payments source 2025-03-11 · E.R. Squibb & Sons, L.L.C. · $4.94 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $6.90 · Open Payments source 2025-04-16 · E.R. Squibb & Sons, L.L.C. · $5.19 · Open Payments source 2025-04-30 · E.R. Squibb & Sons, L.L.C. · $18.26 · Open Payments source 2025-05-01 · E.R. Squibb & Sons, L.L.C. · $1.79 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $1.74 · Open Payments source 2025-07-15 · E.R. Squibb & Sons, L.L.C. · $13.42 · Open Payments source 2025-08-13 · E.R. Squibb & Sons, L.L.C. · $13.60 · Open Payments source 2025-09-09 · E.R. Squibb & Sons, L.L.C. · $11.42 · Open Payments source 2025-09-23 · E.R. Squibb & Sons, L.L.C. · $26.49 · Open Payments source 2025-10-21 · E.R. Squibb & Sons, L.L.C. · $17.06 · Open Payments source 2025-10-30 · E.R. Squibb & Sons, L.L.C. · $21.23 · Open Payments source 2025-11-24 · E.R. Squibb & Sons, L.L.C. · $11.17 · Open Payments source 2025-11-25 · E.R. Squibb & Sons, L.L.C. · $14.83 · Open Payments source 2025-12-16 · E.R. Squibb & Sons, L.L.C. · $19.71 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$230.87	14	2025
Source payment records 2025-02-13 · Vanda Pharmaceuticals Inc. · $12.60 · Open Payments source 2025-02-25 · Vanda Pharmaceuticals Inc. · $22.59 · Open Payments source 2025-03-18 · Vanda Pharmaceuticals Inc. · $13.06 · Open Payments source 2025-04-18 · Vanda Pharmaceuticals Inc. · $17.59 · Open Payments source 2025-04-22 · Vanda Pharmaceuticals Inc. · $11.71 · Open Payments source 2025-05-21 · Vanda Pharmaceuticals Inc. · $15.88 · Open Payments source 2025-06-05 · Vanda Pharmaceuticals Inc. · $27.47 · Open Payments source 2025-06-25 · Vanda Pharmaceuticals Inc. · $6.48 · Open Payments source 2025-07-10 · Vanda Pharmaceuticals Inc. · $35.77 · Open Payments source 2025-09-10 · Vanda Pharmaceuticals Inc. · $11.94 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $27.77 · Open Payments source 2025-12-01 · Vanda Pharmaceuticals Inc. · $11.27 · Open Payments source 2025-12-04 · Vanda Pharmaceuticals Inc. · $3.52 · Open Payments source 2025-12-16 · Vanda Pharmaceuticals Inc. · $13.22 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$196.55	16	2025
Source payment records 2025-01-15 · Alkermes, Inc. · $20.40 · Open Payments source 2025-01-23 · Alkermes, Inc. · $19.54 · Open Payments source 2025-02-13 · Alkermes, Inc. · $3.67 · Open Payments source 2025-03-06 · Alkermes, Inc. · $25.18 · Open Payments source 2025-03-13 · Alkermes, Inc. · $2.71 · Open Payments source 2025-03-13 · Alkermes, Inc. · $6.76 · Open Payments source 2025-05-22 · Alkermes, Inc. · $18.58 · Open Payments source 2025-07-10 · Alkermes, Inc. · $5.08 · Open Payments source 2025-07-24 · Alkermes, Inc. · $17.44 · Open Payments source 2025-08-05 · Alkermes, Inc. · $12.21 · Open Payments source 2025-09-23 · Alkermes, Inc. · $1.93 · Open Payments source 2025-09-23 · Alkermes, Inc. · $9.37 · Open Payments source 2025-10-08 · Alkermes, Inc. · $21.41 · Open Payments source 2025-11-18 · Alkermes, Inc. · $1.11 · Open Payments source 2025-11-18 · Alkermes, Inc. · $14.32 · Open Payments source 2025-12-09 · Alkermes, Inc. · $16.84 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$151.33	13	2025
Source payment records 2025-01-13 · ABBVIE INC. · $5.29 · Open Payments source 2025-01-28 · ABBVIE INC. · $8.38 · Open Payments source 2025-03-12 · ABBVIE INC. · $12.50 · Open Payments source 2025-04-03 · ABBVIE INC. · $10.54 · Open Payments source 2025-04-16 · ABBVIE INC. · $14.94 · Open Payments source 2025-05-29 · ABBVIE INC. · $5.53 · Open Payments source 2025-06-09 · ABBVIE INC. · $22.96 · Open Payments source 2025-07-14 · ABBVIE INC. · $5.67 · Open Payments source 2025-07-21 · ABBVIE INC. · $11.42 · Open Payments source 2025-08-11 · ABBVIE INC. · $14.55 · Open Payments source 2025-09-22 · ABBVIE INC. · $15.74 · Open Payments source 2025-10-23 · ABBVIE INC. · $4.51 · Open Payments source 2025-11-03 · ABBVIE INC. · $19.30 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$84.95	5	2025
Source payment records 2025-02-18 · Neurocrine BioSciences, Inc. · $14.12 · Open Payments source 2025-04-15 · Neurocrine BioSciences, Inc. · $14.67 · Open Payments source 2025-09-04 · Neurocrine BioSciences, Inc. · $14.69 · Open Payments source 2025-11-17 · Neurocrine BioSciences, Inc. · $17.09 · Open Payments source 2025-12-22 · Neurocrine BioSciences, Inc. · $24.38 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$55.62	3	2025
Source payment records 2025-04-08 · Corium, LLC · $10.59 · Open Payments source 2025-08-12 · Corium, LLC · $20.82 · Open Payments source 2025-09-18 · Corium, LLC · $24.21 · Open Payments source
HETLIOZ Normalized: hetlioz	Drug	Vanda Pharmaceuticals Inc.	$55.59	3	2025
Source payment records 2025-05-21 · Vanda Pharmaceuticals Inc. · $15.88 · Open Payments source 2025-09-10 · Vanda Pharmaceuticals Inc. · $11.94 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $27.77 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$46.96	3	2025
Source payment records 2025-04-23 · Janssen Pharmaceuticals, Inc · $15.11 · Open Payments source 2025-04-30 · Janssen Pharmaceuticals, Inc · $15.50 · Open Payments source 2025-09-29 · Janssen Pharmaceuticals, Inc · $16.35 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$46.48	3	2025
Source payment records 2025-05-28 · Otsuka America Pharmaceutical, Inc. · $13.88 · Open Payments source 2025-09-02 · Otsuka America Pharmaceutical, Inc. · $17.87 · Open Payments source 2025-11-04 · Otsuka America Pharmaceutical, Inc. · $14.73 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Lundbeck LLC	$39.85	2	2025
Source payment records 2025-04-03 · Lundbeck LLC · $18.98 · Open Payments source 2025-07-29 · Lundbeck LLC · $20.87 · Open Payments source
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$37.49	2	2025
Source payment records 2025-06-02 · Otsuka America Pharmaceutical, Inc. · $21.90 · Open Payments source 2025-07-07 · Otsuka America Pharmaceutical, Inc. · $15.59 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$33.37	2	2025
Source payment records 2025-03-19 · Teva Pharmaceuticals USA, Inc. · $11.91 · Open Payments source 2025-12-03 · Teva Pharmaceuticals USA, Inc. · $21.46 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$29.97	2	2025
Source payment records 2025-05-14 · Axsome Therapeutics, Inc. · $15.46 · Open Payments source 2025-10-16 · Axsome Therapeutics, Inc. · $14.51 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$21.33	1	2025
Source payment records 2025-11-25 · Collegium Pharmaceutical, Inc. · $21.33 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$16.67	1	2025
Source payment records 2025-02-13 · Supernus Pharmaceuticals, Inc. · $16.67 · Open Payments source
VIVITROL Normalized: vivitrol	Drug	Alkermes, Inc.	$14.93	1	2025
Source payment records 2025-07-30 · Alkermes, Inc. · $14.93 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$14.75	1	2025
Source payment records 2025-08-21 · Janssen Pharmaceuticals, Inc · $14.75 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ABILIFY MAINTENA abilify maintena	2025	Abilify Maintena	2024	19 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	142	exact normalized	Medicare Part D
FANAPT fanapt	2025	Fanapt	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	59 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	258	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	44 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	26 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	46 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	CREON open payments reported associated product	CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608	Creon · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	79	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	46	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	77	15
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	142	24
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	142	24
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	258	46
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	XARELTO open payments reported associated product	CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970	Xarelto · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	19	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	59	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	19	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO open payments reported associated product	CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192	Austedo · 2024 Exact normalized brand match · 1 Part D row	23	suppressed by CMS
Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference	2025	FANAPT open payments reported associated product	CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535	Fanapt · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	638	105
Benztropine Mesylate	Benztropine Mesylate	527	83
Lisinopril	Lisinopril	489	79
Trazodone Hcl	Trazodone Hcl	482	100
Quetiapine Fumarate	Quetiapine Fumarate	465	69
Buspirone Hcl	Buspirone Hcl	453	84
Risperidone	Risperidone	438	77
Omeprazole	Omeprazole	423	64
Divalproex Sodium	Divalproex Sodium	392	59
Olanzapine	Olanzapine	375	63
Metformin Hcl	Metformin Hcl	371	64
Levothyroxine Sodium	Levothyroxine Sodium	362	59
Amlodipine Besylate	Amlodipine Besylate	340	44
Sertraline Hcl	Sertraline Hcl	333	56
Rosuvastatin Calcium	Rosuvastatin Calcium	322	37
Haloperidol	Haloperidol	289	43
Mirtazapine	Mirtazapine	271	45
Pantoprazole Sodium	Pantoprazole Sodium	263	40
Invega Sustenna	Paliperidone Palmitate	258	46
Tamsulosin Hcl	Tamsulosin Hcl	249	42
Gabapentin	Gabapentin	233	40
Metoprolol Tartrate	Metoprolol Tartrate	206	29
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	195	30
Lurasidone Hcl	Lurasidone Hcl	194	35
Lamotrigine	Lamotrigine	192	25
Metoprolol Succinate	Metoprolol Succinate	192	30
Hydroxyzine Pamoate	Hydroxyzine Pamoate	186	42
Divalproex Sodium Er	Divalproex Sodium	182	29
Losartan Potassium	Losartan Potassium	176	28
Meloxicam	Meloxicam	176	26
Ibuprofen	Ibuprofen	172	57
Furosemide	Furosemide	169	32
Aripiprazole	Aripiprazole	167	31
Levetiracetam	Levetiracetam	157	22
Fluticasone Propionate	Fluticasone Propionate	156	29
Caplyta	Lumateperone Tosylate	142	24
Famotidine	Famotidine	130	23
Vascepa	Icosapent Ethyl	129	15
Lithium Carbonate	Lithium Carbonate	125	22
Fluoxetine Hcl	Fluoxetine Hcl	121	21
Hydrochlorothiazide	Hydrochlorothiazide	118	24
Clonazepam	Clonazepam	117	24
Citalopram Hbr	Citalopram Hydrobromide	116	21
Paroxetine Hcl	Paroxetine Hcl	113	20
Potassium Chloride	Potassium Chloride	112	20
Montelukast Sodium	Montelukast Sodium	105	19
Simvastatin	Simvastatin	103	15
Ropinirole Hcl	Ropinirole Hcl	101	15
Prazosin Hcl	Prazosin Hcl	99	16
Propranolol Hcl	Propranolol Hcl	98	15
Donepezil Hcl	Donepezil Hcl	97	16
Venlafaxine Hcl Er	Venlafaxine Hcl	97	18
Escitalopram Oxalate	Escitalopram Oxalate	92	13
Esomeprazole Magnesium	Esomeprazole Magnesium	92	16
Bupropion Xl	Bupropion Hcl	91	12
Emtricitabine-Tenofovir Disop	Emtricitabine/Tenofovir (Tdf)	91	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	89	27
Oxcarbazepine	Oxcarbazepine	89	13
Fenofibrate	Fenofibrate Nanocrystallized	87	11
Bupropion Hcl Sr	Bupropion Hcl	86	12
Loperamide	Loperamide Hcl	80	45
Symbicort	Budesonide/Formoterol Fumarate	80	12
Linzess	Linaclotide	79	suppressed
Memantine Hcl	Memantine Hcl	78	15
Eliquis	Apixaban	77	15
Carvedilol	Carvedilol	76	13
Olanzapine Odt	Olanzapine	76	suppressed
Haloperidol Decanoate	Haloperidol Decanoate	75	14
Clopidogrel	Clopidogrel Bisulfate	74	16
Quetiapine Fumarate Er	Quetiapine Fumarate	74	suppressed
Atenolol	Atenolol	70	suppressed
Ozempic	Semaglutide	69	11
Duloxetine Hcl	Duloxetine Hcl	67	14
Januvia	Sitagliptin Phosphate	67	suppressed
Sucralfate	Sucralfate	66	14
Gemfibrozil	Gemfibrozil	64	suppressed
Doxepin Hcl	Doxepin Hcl	63	suppressed
Lithium Carbonate Er	Lithium Carbonate	63	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	60	11
Topiramate	Topiramate	60	12
Ingrezza	Valbenazine Tosylate	59	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	58	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	55	15
Klor-Con M10	Potassium Chloride	55	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	54	11
Farxiga	Dapagliflozin Propanediol	52	suppressed
Guanfacine Hcl	Guanfacine Hcl	52	suppressed
Clonidine Hcl	Clonidine Hcl	49	17
Lovastatin	Lovastatin	49	suppressed
Allopurinol	Allopurinol	48	suppressed
Glipizide	Glipizide	48	suppressed
Paliperidone Er	Paliperidone	48	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	47	suppressed
Vraylar	Cariprazine Hcl	46	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	45	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	45	14
Lybalvi	Olanzapine/Samidorphan Malate	44	suppressed
Tramadol Hcl	Tramadol Hcl	44	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	44	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	43	suppressed
Ondansetron Hcl	Ondansetron Hcl	42	30
Prenatal Vitamin Plus Low Iron	Pnv,calcium 72/Iron/Folic Acid	42	suppressed
Breo Ellipta	Fluticasone/Vilanterol	41	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	41	suppressed
Finasteride	Finasteride	39	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	38	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	38	suppressed
Bumetanide	Bumetanide	37	suppressed
Fenofibrate	Fenofibrate	37	suppressed
Glipizide Er	Glipizide	37	suppressed
Naproxen	Naproxen	37	suppressed
Lorazepam	Lorazepam	36	suppressed
Megestrol Acetate	Megestrol Acetate	35	suppressed
Alendronate Sodium	Alendronate Sodium	34	suppressed
Dexlansoprazole Dr	Dexlansoprazole	34	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Asenapine Maleate	Asenapine Maleate	32	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	31	20
Dutasteride	Dutasteride	31	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	suppressed
Malathion	Malathion	31	31
Baclofen	Baclofen	30	suppressed
Celecoxib	Celecoxib	30	suppressed
Prednisone	Prednisone	29	suppressed
Desmopressin Acetate	Desmopressin Acetate	28	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	28	suppressed
Metformin Hcl Er	Metformin Hcl	28	suppressed
Primidone	Primidone	28	suppressed
Tizanidine Hcl	Tizanidine Hcl	28	suppressed
Ventolin Hfa	Albuterol Sulfate	28	18
Azithromycin	Azithromycin	27	24
Tradjenta	Linagliptin	27	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	11
Rexulti	Brexpiprazole	26	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	26	suppressed
Trulicity	Dulaglutide	26	suppressed
Amiodarone Hcl	Amiodarone Hcl	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Naltrexone Hcl	Naltrexone Hcl	25	suppressed
Ondansetron Odt	Ondansetron	25	16
Captopril	Captopril	24	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	24	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	24	suppressed
Austedo	Deutetrabenazine	23	suppressed
Lactulose	Lactulose	23	suppressed
Latuda	Lurasidone Hcl	23	20
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	23	suppressed
Zafirlukast	Zafirlukast	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Spironolactone	Spironolactone	22	suppressed
Valsartan	Valsartan	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Permethrin	Permethrin	20	20
Abilify Maintena	Aripiprazole	19	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	19	suppressed
Amantadine	Amantadine Hcl	18	suppressed
Meclizine Hcl	Meclizine Hcl	18	11
Perphenazine	Perphenazine	18	suppressed
Calcitriol	Calcitriol	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	17	suppressed
Ketoconazole	Ketoconazole	17	suppressed
Nystatin	Nystatin	17	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	17	suppressed
Jardiance	Empagliflozin	16	suppressed
Risperidone Odt	Risperidone	16	suppressed
Brilinta	Ticagrelor	15	suppressed
Estradiol	Estradiol	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Fanapt	Iloperidone	14	suppressed
Raloxifene Hcl	Raloxifene Hcl	14	suppressed
Valproic Acid	Valproic Acid (As Sodium Salt)	14	suppressed
Clozapine	Clozapine	13	suppressed
Dexilant	Dexlansoprazole	13	suppressed
Diclofenac Potassium	Diclofenac Potassium	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Gemtesa	Vibegron	13	suppressed
Hydroxyurea	Hydroxyurea	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Tresiba Flextouch U-200	Insulin Degludec	13	suppressed
Cephalexin	Cephalexin	12	11
Clonidine	Clonidine	12	suppressed
Creon	Lipase/Protease/Amylase	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Lacosamide	Lacosamide	12	suppressed
Levonest	Levonorgestrel/Ethin.Estradiol	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	12
Perseris	Risperidone	12	suppressed
Pravastatin Sodium	Pravastatin Sodium	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Tetrabenazine	Tetrabenazine	12	suppressed
Carbamazepine Er	Carbamazepine	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Promethazine Hcl	Promethazine Hcl	11	suppressed
Trintellix	Vortioxetine Hydrobromide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$65,154.04 · 232 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, REXULTI, SPRAVATO, UZEDY, VIVITROL, VRAYLAR	17	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Abilify Maintena play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error